Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - tablets - amoxillin 500mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - film coated tablets - amoxicillin 875mg, clavulanic acid 125mg - dafraclav® is indicated in the treatment of the following infections caused by the microorganisms indicated below. upper respiratory tract infections (including otitis media and sinusitis) due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. lower respiratory tract infections due to beta-lactamase producing strains of haemophilus influenzae and moraxella catarrhalis. skin and skin structure infections due to beta-lactamase producing strains of staphylococcus aureus, escherichia coli and klebsiella spp. urinary tract infections. since dafraclav® contains amoxicillin, it can be used in the treatment of infections caused by bacteria susceptible to ampicillin. additionally, if in a mixed infection a microorganisms is susceptible to ampicillin and the other which is a beta-lactamase producer is susceptible to dafraclav®, such an infection can be treated by the administration of dafraclav® alone, addition of another antibiotic is not required.

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - ibuprofen - film-coated tablet - 200 milligram(s) - propionic acid derivatives; ibuprofen - propionic acid derivatives - for the short-term management of mild to moderate pain such as headache, dental pain, period pain, muscular strain and backache and for the management of feverishness and the symptoms of colds and influenza

European Union - English - EMA (European Medicines Agency)

teva b.v. - rasagiline - parkinson disease - anti-parkinson drugs - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.

European Union - English - EMA (European Medicines Agency)

teva b.v. - rasagiline - parkinson disease - anti-parkinson drugs - rasagiline ratiopharm is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

European Union - English - EMA (European Medicines Agency)

biogen idec ltd - daclizumab - multiple sclerosis - immunosuppressants - zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (rms).

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - ibuprofen 200mg; ibuprofen 200mg - film coated tablet - 200 mg - active: ibuprofen 200mg excipient: colloidal silicon dioxide hypromellose e-15 magnesium stearate maize starch propylene glycol purified talc purified water sodium laurilsulfate titanium dioxide active: ibuprofen 200mg excipient: colloidal silicon dioxide hypromellose e-15 magnesium stearate maize starch methyl hydroxybenzoate propyl hydroxybenzoate propylene glycol purified talc purified water sodium laurilsulfate titanium dioxide - ibugesic tablets are indicated for analgesic and anti-inflammatory effect in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies. in the treatment of non-articular rheumatic conditions, ibugesic tablets are indicated in periarticular conditions such as frozen shoulder (capsulitis), bursitis, tendonitis, tenosynovitis and low-back pain. ibugesic tablets can also be used in soft-tissue injuries such as sprains and strains. ibugesic tablets are also indicated for its analgesic effect in the relief of mild to moderate pain such as dysmenorrhoea, dental and post-operative pain. ibugesic tablets are also indicated for the relief of neuralgia, migraine, headache, feverishness and for the relief of the symptoms of cold and influenza.

Australia - English - Department of Health (Therapeutic Goods Administration)

shen neng herbal medicines group pty ltd - zingiber officinale, quantity: 800 microgram (equivalent: zingiber officinale, qty 5.74 mg); citrus reticulata, quantity: 5.3 mg (equivalent: citrus reticulata, qty 37.91 mg; equivalent: oxedrine, qty 830 microgram); pogostemon cablin, quantity: 7.917 mg (equivalent: pogostemon cablin, qty 56.61 mg); wolfiporia cocos, quantity: 18.95 mg (equivalent: wolfiporia cocos, qty 18.95 mg); perilla frutescens, quantity: 2.65 mg (equivalent: perilla frutescens, qty 18.95 mg); pinellia ternata, quantity: 5.3 mg (equivalent: pinellia ternata, qty 37.91 mg); magnolia officinalis, quantity: 5.3 mg (equivalent: magnolia officinalis, qty 37.91 mg); glycyrrhiza uralensis, quantity: 1.779 mg (equivalent: glycyrrhiza uralensis, qty 12.72 mg); platycodon grandiflorus, quantity: 37.91 mg (equivalent: platycodon grandiflorus, qty 37.91 mg); ziziphus jujuba, quantity: 1.3258 mg (equivalent: ziziphus jujuba, qty 9.48 mg); glycyrrhiza uralensis, quantity: 25.19 mg (equivalent: glycyrrhiza uralensis, qty 25.19 mg); angelica dahurica, quantity: 18.95 mg (equivalent: angelica dahurica, qty 18.95 mg); atractylodes macrocephala, quantity: 5.3 mg (equivalent: atractylodes macrocephala, qty 37.91 mg) - pill - excipient ingredients: maltose; purified talc; maize starch - traditionally used in chinese medicine to harmonise the middle-burner (spleen and stomach) ; traditionally used in chinese medicine to clear/dry/drain/eliminate/resolve dampness ; traditionally used in chinese medicine to regulate qi ; traditionally used in chinese medicine to decrease/reduce/relieve diarrhoea ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of indigestion/dyspepsia ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of stomach upsets ; traditionally used in chinese medicine to antiemetic/decrease/reduce/relieve vomiting ; traditionally used in chinese medicine to decrease/reduce/relieve symptoms of common cold

Australia - English - Department of Health (Therapeutic Goods Administration)

shen neng herbal medicines group pty ltd - angelica dahurica,areca catechu,atractylodes macrocephala,citrus reticulata,glycyrrhiza uralensis,magnolia officinalis,perilla frutescens,pinellia ternata,platycodon grandiflorus,pogostemon cablin,wolfiporia cocos,zingiber officinale,ziziphus jujuba -

Australia - English - Department of Health (Therapeutic Goods Administration)

shen neng herbal medicines group pty ltd - chrysanthemum sinense,forsythia suspensa,glycyrrhiza uralensis,mentha haplocalyx,morus alba,perilla frutescens,phragmites australis,platycodon grandiflorus -